Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 15/20 | 0.39 |
| ▸ | TAB1 | Q15750 | 15/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660959 | 0.83 | MAP3K7 (0.44) | MAP3K7TAB1KDRAURKBNAMPT | |
| SCHEMBL659236 | 0.81 | TLR8 (0.40) | TLR8MAP3K7TAB1MAPTKDR | |
| SCHEMBL659267 | 0.79 | MAP3K7 (0.49) | TLR8MAP3K7TAB1MAPTKDR | |
| SCHEMBL660235 | 0.71 | LMNA (0.44) | TLR8MAP3K7TAB1MAPT | |
| SCHEMBL664646 | 0.69 | MAP3K7 (0.64) | TLR8MAP3K7TAB1KDRAURKB | |
| SCHEMBL21894106 | 0.69 | GSK3B (0.42) | KDRNAMPTCCNT1CDK1CCNB1 | |
| SCHEMBL659131 | 0.66 | MAP3K7 (0.44) | TLR8MAP3K7TAB1MAPTKDR | |
| SCHEMBL658331 | 0.66 | MAP3K7 (0.43) | MAP3K7TAB1KDRAURKB | |
| SCHEMBL659522 | 0.66 | QPCT (0.39) | TLR8MAP3K7TAB1MAPT | |
| SCHEMBL658805 | 0.65 | MAP3K7 (0.48) | TLR8MAP3K7TAB1KDRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | TLR8 2644/4885MAP3K7 5/4885TAB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.